{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A 1-year pragmatic randomized clinical trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A 1-year pragmatic randomized clinical trial was conducted in an academic medical institution."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants included persons aged 21 to 65 years with type 2 diabetes diagnosed more than 1 year before the study; their body mass index was 30 to 42 (calculated as weight in kilograms divided by height in meters squared) and hemoglobin A 1c (HbA 1c ) was greater than or equal to 6.5%."
      },
      "Intervention": {
        "score": 2,
        "evidence": "RYGB (n = 19) or Why WAIT (n = 19) including 12 weekly multidisciplinary group lifestyle, medical, and educational sessions with monthly follow-up thereafter."
      },
      "Objective": {
        "score": 1,
        "evidence": "To test the feasibility of methods to conduct a larger multisite trial to determine the long-term effect of Roux-en-Y gastric bypass (RYGB) surgery compared with an intensive diabetes medical and weight management (Weight Achievement and Intensive Treatment [Why WAIT]) program for type 2 diabetes."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Proportion of patients with fasting plasma glucose levels less than 126 mg/dL and HbA 1c less than 6.5%, measures of cardiometabolic health, and patient-reported outcomes."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "RYGB (n = 19) or Why WAIT (n = 19)"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "At 1 year, the proportion of patients achieving HbA 1c below 6.5% and fasting glucose below 126 mg/dL was higher following RYGB than Why WAIT (58% vs 16%, respectively; P = .03)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  },
  "model": "gpt-4o"
}